Sanofi creates European drug ingredients business
When completed, the planned company will allegedly rank as the world’s second largest API company with approximately €1 billion in expected sales by 2022.
Read More
Tag: ingredients
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
